Compare Amgen, Inc. (AMGN) vs Brookfield Infrastructure Partners LP (BIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Brookfield Infrastructure Partners LP — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Brookfield Infrastructure Partners LP trades at $37.65 (market cap $17.26B). The key difference: Amgen, Inc. is far larger — about 11.4× Brookfield Infrastructure Partners LP's market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.83%). Which is the better fit depends on your goals.
| AMGN | BIP | |
|---|---|---|
Market Cap | $196.12B | $17.26B |
Sector | Health | Industrials |
52-Week High | $388.16 | $40.08 |
52-Week Low | $271.18 | $29.81 |
Enterprise Value | $241.41B | $78.93B |
Dividend Yield | 2.77% | 4.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Brookfield Infrastructure Partners (BIP) trades at $37.65, up 0.97% today, with a bullish technical signal from moving averages. The stock shows mixed earnings performance but maintains strong cash flows and a 5% dividend yield. Recent news highlights its infrastructure assets as resilient to economic uncertainty, with accelerating growth despite a 15% year-to-date decline. Analyst consensus is strongly bullish with an $45.50 price target, citing undervaluation and AI data center tailwinds.
BIP offers attractive total return potential through dividend income and growth from inflation-linked contracts, but faces execution risks from high leverage and interest rate sensitivity. Near-term catalysts include Q2 2026 earnings on July 30, 2026, while misses in recent quarters and net income margin compression warrant caution for growth-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →
